Pfizer to bolster rare disease portfolio with FoldRx acquisition

Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make an upfront payment and further payments depending on the achievement of certain milestones.

Earlier this year, the pharma giant created a rare disease research unit to discover novel medicines for diseases affecting fewer than 200,000 patients globally (